Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

This study is testing a combination of the immunotherapy drug nivolumab (which helps the immune system fight cancer) with chemotherapy for people with primary tracheal squamous cell carcinoma — a rare cancer of the windpipe — that cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with tracheal squamous cell carcinoma confirmed by biopsy - Scans confirm the cancer has not spread to distant parts of the body - Your physical condition is good (ECOG 0–1) - The tumor has been assessed as early or locally advanced and treatable with intent to cure **You may NOT be eligible if...** - Your cancer has spread beyond the chest to distant organs - You have serious autoimmune conditions that could be worsened by immunotherapy - You have already received chemotherapy or radiation for this cancer - Your organ function (heart, lungs, kidneys, liver) is not adequate for treatment Talk to your doctor to see if this trial is right for you.